Disclosure of the October monthly exercise status for the Docirbrutinib (AS-1763) development incentive stock options. Granted shares: 191,900 shares; number of stock acquisition rights exercised: 1,919 (after applying the exercise restriction of 0.99% of total issued); unexercised rights: 73,784 units; total issued shares during the period: 19,196,700 shares.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4572","jir_company_name":"Carna Biosciences, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4572-20261102-01.pdf","jir_short_summary":"Disclosure of the October monthly exercise status for the Docirbrutinib (AS-1763) development incentive stock options. Granted shares: 191,900 shares; number of stock acquisition rights exercised: 1,919 (after applying the exercise restriction of 0.99% of total issued); unexercised rights: 73,784 units; total issued shares during the period: 19,196,700 shares.","jir_summary":"### Summary of the News\nCarna Biosciences, Inc. announced the monthly exercise status for October 2026 of the Docirbrutinib (AS-1763) development incentive stock options (with exercise price adjustment clause). The number of shares granted during the applicable month was 191,900 shares. The number of stock acquisition rights exercised was 1,919 units (with an exercise restriction applied equal to 0.99% of the total issued). The total unexercised stock acquisition rights amounted to 73,784 units (equivalent to 7,378,400 shares).\n\n### Impact on Shareholders and Background\nThe exercise ratio is rounded down at the third decimal place, and unexercised rights remain at this time. The exercise status of stock acquisition rights is influenced by the number of publicly tradable shares and the conditions of the exercise restriction; therefore, trends should be monitored in future monthly disclosures.","jir_financial_highlights":"Granted shares (shares): 191,900 shares (Unknown)\nNumber of stock acquisition rights exercised (units): 1,919 units (Unknown)\nTotal issued (shares): Unknown (Unknown)","jir_category":"","jir_hashtags":"#CarnaBiosciences, #StockOptionTrends","jir_key_figures":"Granted shares (shares): 191,900 shares\nNumber of stock acquisition rights exercised (units): 1,919 units\nNumber of unexercised stock acquisition rights: 73,784 units","jir_meta_title":"Carna Biosciences, Inc. | Monthly Exercise Status of Docirbrutinib Development Incentive Stock Options\uff5cOctober 2026","jir_meta_description":"Carna Biosciences, Inc. published the October monthly exercise status for Docirbrutinib development incentive stock options. Granted shares: 191,900 shares; exercised rights: 1,919 units; unexercised: 73,784 units. Exercise ratio relative to 19,196,700 issued shares is 0.99%.","jir_og_title":"Carna Biosciences, Inc. Announces Monthly Exercise Status of Stock Acquisition Rights","jir_og_description":"Disclosure of October exercise status for Docirbrutinib development incentive stock options: granted shares 191,900 shares; exercised rights 1,919 units; unexercised 73,784 units. Total issued shares: 19,196,700 shares.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59427,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-140349","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n